EMA Authorised: Suboxone (buprenorphine;naloxone) — Indivior Europe Limited

View source ↗

Summary

EMA has authorised Suboxone (buprenorphine/naloxone) for opioid-related disorders, with Indivior Europe Limited as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• SUBOXONE (buprenorphine hydrochloride, naloxone hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Opioid-Related Disorders. MAH: Indivior Europe Limited. Decision date: 24/07/2024